A new study shows Crizotinib (Pfizer) acts on small cell lung cancers, specifically (ALK) anaplastic lymphoma kinase tumors, showing a 57% response rate and an 87% disease control rate at 8 weeks. "This response rate is unprecedented in lung cancer," said Anil Potti, MD, associate professor of medicine at Duke University. More study will need to be done, of course, but the ramifications are inspiring. In a related story, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report that combination drug therapy from the very start of therapy can produce good results.
No comments:
Post a Comment